Vaccination of foals with a modified live, equid herpesvirus-1 gM deletion mutant (RacHΔgM) confers partial protection against infection by Kydd, Julia H. et al.
Vaccination of foals with a modified live, equid herpesvirus-1 gM deletion mutant 
(RacHgM) confers partial protection against infection  
 
Julia H. Kyddai*, Duncan Hannantai, Robert S Robinsonb, Neil Bryanta, Nikolaus 
Osterriederc  
 
aCentre for Preventive Medicine, Animal Health Trust, Lanwades Park, Kentford, 
Newmarket, Suffolk CB8 7UU, United Kingdom  
 
bSchool of Veterinary Medicine and Science, University of Nottingham, Sutton 
Bonington, Loughborough, Leicestershire LE12 5RD, United Kingdom 
 
cInstitut für Virologie, Robert von Ostertag-Haus, Zentrum für Infektionsmedizin, 
Robert von Ostertag-Str. 7-13, 14163 Berlin, Germany 
 
iCurrent address: School of Veterinary Medicine and Science, University of 
Nottingham, Sutton Bonington, Loughborough, Leicestershire LE12 5RD, United 
Kingdom 
 
*corresponding author. https:\\orcid.org/0000-0002-2648-6999 
 
Short title: Vaccination of foals with EHV-1 gM deletion mutant  
 
No. words in abstract: 245 
No. words in text: Introduction to Conclusion inclusive: 6435 
No. of references: 95 
Highlights  
 Vaccination of foals with an EHV-1 gM-  MLV stimulated CF and VN antibodies  
 Vaccination resulted in reduced clinical scores on challenge infection 
 EHV-1 specific mucosal antibody and CTL activity were not induced by 
vaccination 




Equid herpesvirus-1 (EHV-1) causes respiratory and neurological disease and late 
gestation abortion in pregnant mares. Current vaccines contain either inactivated or 
live EHV-1, but fail to provide complete clinical or virological protection, namely 
prevention of nasopharyngeal shedding and cell-associated viraemia. Thus, the 
development of novel products, such as modified live virus (MLV) vaccines which 
stimulate virus-specific, humoral and cell mediated immune responses more 
effectively remains a priority. Two groups of weaned foals (n=6 each group) were 
used in a longitudinal, prospective, experimental study to evaluate immune 
responses elicited by two vaccinations with a glycoprotein M (gM) deletion mutant of 
EHV-1 (RacHdeltagM). Following two concurrent intranasal and intramuscular 
inoculations six weeks apart, vaccinated (8.4+0.2 months old) and control foals 
(6.2+0.4 months) were challenge infected intranasally with EHV-1 Ab4/8 four weeks 
after the second vaccination and clinical signs and virological replication measured. 
Vaccination caused no adverse events, but did stimulate significantly higher 
complement fixing and virus neutralizing antibodies in serum compared with control 
foals at either equivalent or pre-vaccination time points. Virus-specific 
nasopharyngeal antibody levels and cytotoxic T lymphocyte responses were not 
significantly different between the groups.  Following challenge infection, these 
immune responses were associated with a reduction in clinical signs and virological 
replication in the vaccinated foals, including a reduction in duration and magnitude of 
pyrexia, nasopharyngeal shedding and cell-associated viraemia. We conclude that 
the RacHgM MLV primed EHV-1-specific humoral immune responses in weaned 
foals. However, complete virological protection by vaccination against EHV-1 
requires further research. 
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1. Introduction  
The ubiquitous alphaherpesvirus equid herpesvirus-1 (EHV-1) is responsible for 
respiratory and neurological disease in all horses and abortion in pregnant mares [1]. 
Abortion and neurological disease are the consequences of a cell-associated 
viraemia and endothelial cell infection, which leads to vascular pathology in the 
vulnerable pregnant uterus or spinal cord [2, 3].  
 
Vaccination against EHV-1 aims to prevent nasopharyngeal virus shedding and cell-
associated viraemia, which will eliminate within herd transmission or endothelial cell 
infection and thrombosis respectively [4]. Experimentally, a reduction in the duration 
and magnitude of these virological parameters is associated with high pre-infection 
titres of virus neutralizing (VN) antibody, respiratory mucosal IgG4 / IgG7 isotypes 
and high frequencies of precursor or memory cytotoxic T lymphocytes (CTL) in 
blood, sometimes combined with virus-specific mucosal antibodies in the 
nasopharynx [4, 5].  However, current vaccines which contain either inactivated virus 
with licensed adjuvants or attenuated, modified live virus [6], fail to stimulate the 
comprehensive range of immune responses required. The efficacy of these vaccines 
is variable, probably due to multiple factors including host, antigenic load and 
challenge infection method, but none prevent cell-associated viraemia completely.  
Thus, in the face of ongoing outbreaks of EHV-1 abortion in vaccinated horses [7], 
there is an urgent need to identify novel and safe but commercially practical vaccine 
formulations that stimulate long-lived and effective immune responses, particularly 
CTL leading to complete clinical and virological protection against EHV-1. Modified 
live virus vaccines (MLV) have been proposed as suitable candidates [8, 9]. 
 
Examples of the success of MLVs under field conditions include use of a modified 
live gE deletion mutant to eradicate bovine herpesvirus-1 (BHV-1) from some 
European countries [10]. In pigs, management and a gI deletion mutant of 
pseudorabies virus reduced the prevalence of disease in a large field study [11]. In 
young horses, EHV-1 gE/gI deletion mutants provided partial protection against 
respiratory disease [12, 13]. In Japanese Thoroughbred racehorses, a live 
attenuated EHV-1 / EHV-4 vaccine (ERPL, Nisseiken, Tokyo, Japan) stimulated 
higher VN antibody titres than the inactivated virus vaccine used previously and its 
use was also associated with a reduction in the frequency of EHV-1 outbreaks [14]. 
Live attenuated EHV-1 vaccines Rhinomune® (Boehringer Ingelheim) or 
Prevaccinol® (MSD Animal Health), which both contain strain RacH have been 
available commercially in the USA and Europe for decades.  
 
EHV-1 strain RacH was attenuated by 256 passages in porcine embryonic kidney 
cells [15] from the more virulent RacL (clade 4, originally isolated from an aborted 
fetus; [16]).  Sequencing of a plaque isolate, RacL11 has identified entire deletions of 
genes ORF1 (HSV homologue UL56) and ORF2 (no HSV homologue identified to 
date) and in-frame deletions of ORF14, ORF63, EICP0) and two regions in ORF68 
(HSV US2 [17]. In the RacH MLV strain, modification of ORF67 (IR6) is mainly 
responsible for the attenuation, relative to the parental virus [15-20]. In horses, by 
comparison with placebo-vaccinated controls, intramuscular vaccination of adults 
with Rhinomune® (RacH) resulted in a reduction in clinical disease and the amount 
of virus shed from the nasopharynx and cell associated viraemia following challenge 
infection [21, 22]. Intranasal vaccination of weanlings with Rhinomune® failed to 
stimulate either mucosal or systemic antibody after vaccination but after challenge 
infection, was associated with a reduction in clinical and biological signs [23]. RacH 
therefore has shown some promise as an MLV, and thus may benefit from further 
modification. RacH is an old strain but phylogenetic analysis of 80% of the genomes 
of 78 EHV-1 strains, the majority isolated over 35 years in the United Kingdom 
indicated the presence of 13 clades [19]. Further analysis indicated that EHV-1 
evolves very slowly, to the extent that strains isolated currently co-circulate and show 
similarity to much older viruses, including RacL and RacH [15, 18, 19].  
 
Identification of the function of individual EHV-1 proteins, including those associated 
with virulence or correlated with protective immunity [24-26] , enables the informed 
and targeted removal of individual genes: one candidate is glycoprotein gM (gM; 
gp21/22a). This is a non-essential glycoprotein encoded by gene 52 (homologous to 
Herpes simplex virus-1 UL10; [17]) which is involved in virus entry and fusion and 
cell-to-cell spread in both EHV-1 and Herpes Simplex Virus-1 (HSV-1; [27, 28]). 
However RacHgM retains the ability to penetrate, spread from cell-to-cell and 
egress from host cells [27, 29] which is crucial to the development of cell mediated 
immune responses, including CTL activity. In vivo, mice vaccinated once with a 
RacHgM deletion mutant were completely protected against challenge infection 
with the virulent RacL11 strain, suggesting that the RacH gM deletion mutant 
stimulated protective immune responses [30] and may thus be a candidate vaccine 
for horses.    
 
The design of vaccine trials to assess the effectiveness of protection against EHV-1 
is complex, with multiple host, environmental and virological factors potentially 
influencing the outcome [4, 31]. The host complexities include recruitment of animals 
naïve to EHV-1 infection or at least with similar historical infections within a known 
time frame; this ensures similar humoral and cell mediated immunological status, but 
is difficult to assess. The production of specific pathogen-free foals is costly and 
time-consuming [32] so a pragmatic alternative to assess vaccine-induced immunity 
is to identify synchronized pregnant mares, unvaccinated against EHV-1, then use 
their offspring at weaning, when maternally-derived colostrum titres have declined, to 
assess vaccine-induced immunity. Even then the risk of inter-current bacterial 
infection following weaning and mixing of foals from different herds remains high [33, 
34]. Nevertheless, using weaned foals is informative because the current guidance 
states that vaccines against EHV-1 / EHV-4 can be administered to foals from 4-6 
months of age [35]. 
 
The current study tested the hypotheses that vaccination of weaned foals with an 
EHV-1 RacHgM mutant would stimulate immune responses and provide clinical 
and virological protection against challenge infection.  
 
2. Materials and Methods  
2.1 Foals 
The project design, animal care and ethics and genetically modified organisms’ 
safety complied with national laws and institutional regulations. All mares and foals 
were cared for at the Animal Health Trust, Newmarket and were examined by an 
independent clinician prior to vaccination and / or challenge infection. Pregnant 
mares (Welsh Mountain ponies) were kept in two herds according to their stage of 
gestation. Mares were vaccinated against influenza virus and with tetanus toxoid 
according to manufacturers’ instructions, but not vaccinated against EHV-1. For the 
vaccinated foals, 4/6 were male and the Major Histocompatibility Complex (MHC) 
class I haplotypes of both parents were partially known (Table 1). The control foals 
originated from a second herd of outbred mares mated to a single stallion, all were 
female and of unknown genotype. Foals were monitored at monthly intervals from 
birth to plot the decline of colostrum-derived, EHV-1 specific, serum virus 
neutralizing antibodies and to ensure the absence of complement fixing antibodies, 
indicative of recent, natural EHV-1 infection. With the decline of colostral antibody 
and increasing vulnerability of these foals to unplanned respiratory infection, the 
vaccination program was initiated in the six oldest foals 3 weeks after weaning. The 
reasons underlying this decision included the vulnerability of these foals to 
respiratory bacterial infection and inflammatory airway disease, particularly when 
groups of animals are mixed for the first time [33, 34]. The six remaining animals 
were allocated to the control group. As a result, the mean age of vaccinated foals 
was 2.2 months older than the control group.  
 
2.2 EHV-1 glycoprotein M (gM) deletion mutant EHV-1 (RacHgM) 
EHV-1 RacH11gM, a LacZ insertion mutant that still expresses the N-terminal 130 
amino acids was constructed and propagated by five passages in rabbit kidney 13 
(RK13) cells [27, 29]. RacH has deletions in ORF1 (MHC class I downregulation and 
modulation of cytokine responses) and ORF 2 (modulation of cytokine responses) 
and in frame deletions in ORF14, ORF63 and ORF68. The most significant alteration 
which is largely responsible for the attenuation of RacH is the deletion of both copies 
of ORF67 (IR6; HSV US10; [15, 20]).  
 
2.3 Vaccinations and EHV-1 challenge infection 
Three weeks after weaning, vaccinates were inoculated with RacH11gM (Figure 1). 
Vaccinated foals had a mean age of 6.1 + 0.2 months (183.0 + 7.1 days) at the first 
vaccination (Table 1) and were kept on a separate pasture from the control foals. 
Administration was both intramuscularly in the neck by 1” 18g needle and 
intranasally by aerosol spray attached to tubing and syringe and on two occasions 
(V1 and V2), with a 6 week interval. The vaccinated foals were monitored on days 2, 
5, 7 and 9 after V1 for clinical health, including ocular and nasal discharge, pyrexia, 
and cell associated viraemia. Four weeks after V2 (vaccinates) and three weeks 
after weaning (controls), all foals were stabled in pairs within their group and 
immediately challenge infected concurrently. All foals were infected intranasally (day 
0) with 2 x 106.3 50% tissue culture infectious dose (TCID50) of EHV-1 strain Ab4/8 
propagated on equine cells using an aerosol spray [36, 37]. The mean ages of 
vaccinated and control foals were 8.4 + 0.2 or 6.2 + 0.4 months respectively at 
challenge infection.  
 
2.4 Serology 
Serum samples were screened for complement fixing (CF) and virus neutralizing 
(VN) antibody at the time points shown in Figure 2. The V1+0 sample for VN 
antibody testing was taken immediately before first administration of the vaccine. 
Seroconversion was defined as a four-fold increase in titre [37].  
 
2.5 Clinical signs, pyrexia and nasopharyngeal virus shedding 
Following challenge infection, clinical signs were assessed by one operator who was 
blinded to the group status. The presence of mucopurulent nasal or ocular discharge 
at each nostril or eye were assessed and scored as 0 (absent), 1 (present mild), 2 
(present, moderate) or 3 (present, severe). Swelling of the sub-mandibular lymph 
nodes was graded as 0 (barely palpable), 1 (slightly palpable), 2 (easily palpable) or 
3 (enlarged and painful).  Rectal temperatures (pyrexia >38.9oC) and deep 
nasopharyngeal swabs extending approximately 12” were collected daily for 10 days, 
the latter into 2ml of virus transport medium. The Animal Health Trust is an OIE 
reference laboratory for EHV-1 and EHV-4, therefore swabs and blood samples were 
handled according to the OIR manual [36]. Swabs were squeezed using metal 
forceps, which were sterilized between each sample extraction by flaming in alcohol. 
The swab extract was not filtered before titration from neat to 10-10 using log10 
dilutions across a 96 well flat-bottomed micro-titre plate, with 8 replicates per 
sample. Indicator cells were RK13s. Results from this endpoint dilution assay were 
expressed as TCID50/ml.  
 
2.6 Cell associated viraemia 
Peripheral blood samples were collected by jugular venipuncture from vaccinates 
into 10ml evacuated tubes coated with sodium heparin. Blood samples were then 
processed according to the OIE manual [36] using RK13 indicator cells in T25 tissue 
culture flasks. Leukocytes were pelleted by centrifugation of supernatant plasma 
after spontaneous rouleaux formation; Ficoll enrichment of leukocytes was not 
performed. In the absence of cytopathic effect (cpe), cells were passaged a second 
time as described [36]. Results were expressed as positive or negative. Samples 
were collected on days 2, 5, 7, and 9 after V1 and on day 6 after V2. After challenge 
infection, all foals were sampled on alternate days until day 21. 
 
2.7 Measurement of mucosal IgA and IgG in nasal washes 
Nasal washes were performed as described [38], before V1 (vaccinates only), then 
in controls and vaccinates at equivalent time points after vaccination and after 
challenge infection. Samples were clarified by centrifugation, stored at –70oC then 
assayed together following a method adapted from [38]. An optimised dilution of 
EHV-1 strain Ab4 was used as antigen and murine anti-equine IgA monoclonal 
antibody 3E7 (a kind gift from Dr Chris Stokes, University of Bristol), and 
commercial, enzyme conjugated anti-mouse or anti-horse IgG (Kirkegaard & Perry 
Laboratories) were used to detect the respective antibody isotypes. Optical density 
(OD) was read at 450nm. The mean protein concentration (triplicates) of each nasal 
wash was measured by comparing the OD295 generated using a protein assay kit 
(Sigma, Poole, Dorset) with a calibration curve ranging from 0.05 to 1.7 mg/ml 
(absorbance from 0.1 to 1 at OD295). Corrected OD was calculated according to the 
formula: mean OD450 of nasal wash immunoglobulin – non-specific binding OD450 / 
protein concentration (mg/ml). Each assay included positive and negative nasal 
wash controls, selected from pilot assays. 
 
2.8 Cytotoxic T lymphocyte assay 
Peripheral blood mononuclear cells (PBMC) were cryopreserved from all foals and 
MHC class I restricted, EHV-1 specific cytotoxic T lymphocyte activity was measured 
as described previously [39]. The mean of 6 replicates at each effector : target ratio 
(E:T; 100:1, 50:1, 25:1 and 12:1) was calculated and the percent lysis of mock 
infected targets subtracted from that of the autologous EHV-1 infected targets, to 
give a final percent specific lysis. Samples from each foal were tested in a single 
assay, with effector CTL from a hyper-immune pony used as a positive control. 
Statistical analysis was performed on CTL activity at all E:T ratios. 
 
2.9 Statistical Analysis 
For each parameter and sample time point, the mean and standard deviation for each 
group of foals was calculated. The data were checked for normality and homogeneity 
of variance before statistical analysis and were log transformed as necessary. For the 
endpoints (e.g. CF antibody titre) where more than one sample was collected and the 
data points were continuous, a randomized-block ANOVA was performed. The time 
points were grouped into pre-vaccination, after V1, after V2 or post-infection and 
analysed separately. In the analysis, time and vaccination groups were considered the 
factors, with the data blocked by foal identification. Where significant differences were 
detected, individual t-tests were performed to compare the control and vaccinated 
group on a particular day. For discrete endpoints, a non-parametric Mann-Whitney 
(Wilcoxon rank-sum) test was performed. As qualitative data, clinical scores were 
assessed using a non-parametric, one-way ANOVA (Kruskal-Wallis test). CTL data 
were analysed by Fisher’s Exact test. All statistical analysis was performed in Genstat 
17.1. 
 
3. Results  
All foals completed the study, there were no modifications to the study design and 
there were no unexpected adverse events or side effects. 
 
3.1 Pre- and post-vaccination monitoring 
Prior to V1, CF and VN antibody titres were either undetectable or had a reciprocal 
titre of log10 0.2 or 1.7 respectively (<1:20) in all foal samples (Figure 2a & b). 
Vaccinated foals showed no ocular or nasal discharge, pyrexia, clinical abnormalities 
or cell associated viraemia.  
 
3.2 Serology 
Mean CF antibody titres in control foals were low and stable until 2 weeks after 
challenge infection, when all 6 seroconverted to EHV-1 (Figure 2a). Vaccinated foals 
exhibited similar low titres prior to V1, then a non-significant increase in mean titre 
after V1 followed by a significant increase at all post V2 vaccination points compared 
with V1-3m. Samples taken one week after V2 demonstrated seroconversion in 5 / 6 
vaccinated foals, and one foal (1B05) seroconverted 1 week later. Elevated CF 
antibody titres declined thereafter but all 6 vaccinates seroconverted again by 2 
weeks after challenge infection.  Mean CF antibody titres were significantly higher in 
vaccinated versus control foals at all sample points after V2 (p<0.001) and 1 week 
after challenge infection (p<0.001).  
 
VN antibody titres were low in both groups of foals prior to the V1 sampling point 
(Figure 2b; Supplementary Table 1). Thereafter titres in the younger control foals 
declined further, reflecting the level of residual colostral antibody, but subsequently 
increased following challenge infection. In vaccinated foals, titres at the post V2 
vaccination and post infection time points were significantly different from the titre at 
V1+0 (p<0.001). There was a significant difference between the mean VN antibody 
titres of vaccinated versus control foals at V2+2weeks (p<0.001), but not before V1 
(p=0.07) or after challenge infection (p=0.07).  
 
3.3 Clinical signs and virological parameters after challenge infection 
Mean clinical scores amounted to 21.2+7.8 or 8.3+6.2 in the controls and vaccinated 
foals respectively (p=0.03). Pyrexia was detected on day 2 post infection in all 
control foals and 3/6 vaccinated foals (Figure 3a). Mean days of pyrexia were 4.5+1 
in control foals and 1.2+1 in vaccinated foals (p=0.004), but no significance was 
detected for the first or last day of pyrexia. The mean rectal temperature was 
significantly higher in the control group compared with the vaccinated group 
(p<0.001) and at each time point on days 2, 3, 4, 5 and 8 after challenge infection 
(p<0.001).  
 
The mean titres of infectious virus shed from the nasopharynx were higher in the 
control foals (mean 104.93/ml on day 2; Figure 3b), with all 6 animals still shedding 
detectable titres of virus on day 8 (mean 102.67/ml; p<0.01).  The amount of virus 
shed by the vaccinated foals peaked at a mean of 102.32/ml on day 2, but declined 
rapidly thereafter with 4/6 vaccinated foals no longer shedding by day 4. One foal in 
this group had no detectable virus shedding (V6825). There was a significant 
reduction in the total days of nasopharyngeal virus shedding in the vaccinated 
versus control groups (p<0.01; vaccinates mean 2.8+2.3 days, controls mean 
8.3+1.6 days). There was no difference in the first day of nasopharyngeal shedding 
between the groups. In contrast, the last day of nasopharyngeal shedding was 
significantly earlier in the vaccinated group, compared with controls (p<0.05; Figure 
3b; vaccinates day 4.0+3.6 versus controls day 8.8+1.0).  
 
There was a significant difference between the vaccinated and control groups in the 
total days of cell associated viraemia (p<0.002; vaccinates mean 2.5+0.5 days, 
controls 6.2+1.0 days; Figure 3c). In addition, there was a significant difference in the 
last day of cell associated viraemia between the vaccinated and control groups 
(p=0.006; vaccinates day 8.3+2.1 versus controls day 15.3+3.9). Details are shown 
in Supplementary Table 2. 
 
3.4 Mucosal antibody responses 
The levels of nasopharyngeal IgA and IgG were similar in control and RacH11gM 
vaccinated foals. There was a gradual but significant increase in EHV-1 specific, 
nasopharyngeal IgA (p<0.001) and IgG (p<0.001) over the sampling period in both 
groups, but no significant antibody production was induced by vaccination alone 
(Figure 4).  
 
3.5 Cytotoxic T lymphocyte responses 
All foals in both the control and vaccinated groups showed low (<5.6% maximum 
lysis at 100:1 E:T ratio) or undetectable levels of lysis at both time points prior to 
EHV-1 challenge infection (Figure 5). At three weeks after infection, an increase in 
CTL activity above the value of the pre-vaccination sample was detectable in some 
control (2/6) and vaccinated (4/6) foals. By ten weeks after infection, CTL activity 
either increased further or remained stable in most control and vaccinated foals, but 
individual responses were variable. Statistical analysis showed there was a non-
significant trend towards the earlier detection of CTL activity in vaccinated compared 
with control foals using the 100:1 E:T ratios (p=0.06). Analysis of data from all other 
effector to target ratios was also non-significant. 
 
4. Discussion  
This study demonstrated that mucosal and systemic vaccination of weaned foals 
with EHV-1 RacH11gM, a modified live virus vaccine, caused no side effects and 
induced no clinical signs or detectable viral replication. Furthermore, by comparison 
with unvaccinated control foals, vaccination served to prime the foals’ systemic 
humoral immune response and this was associated in vaccinates with a significant 
reduction in mean rectal temperature and temperatures on days 2-5 and 8 post-
infection inclusive, as well as total days and last day of nasopharyngeal virus 
shedding and cell-associated viraemia after challenge infection. Such partial 
protection is found commonly with many types of commercial and experimental EHV-
1 vaccines [13, 22, 40-43], but is particularly encouraging in EHV-1 naïve, weaned 
foals. 
 
Undertaking EHV-1 challenge infection experiments in horses, particularly foals is 
difficult and expensive, especially considering the need to obtain weaned animals of 
approximately the same age and disease-free status. To achieve this in the current 
study, home-bred foals were used. In the United Kingdom, the Horserace Betting 
Levy Board’s Codes of Practice for Equine Infectious Disease (specifically EHV-1) 
recommend keeping pregnant mares of the same gestational age in small groups 
[44]. Thus both herds of pregnant mares were kept separate. At birth, foals were 
kept in the separate groups into which they had been born. This approach aimed to 
reduce any stress in the lactating mares and the consequent risk of reactivation of 
latent EHV-1, which may have transmitted infection to their foals and thus 
compromised the foals’ EHV-1 naïve status. At weaning, the vulnerability of foals to 
inter-current respiratory bacterial infection and inflammatory airway disease, 
particularly when groups of animals are mixed for the first time, is also an ever-
present risk [33, 34]. Therefore, in the current study, prior to vaccination, foals were 
weaned, then maintained in their original birth groups; a strength of this approach is 
that healthy animals which were naïve to EHV-1 were available for the vaccine trial. 
It did however lead to several limitations in the study design. These included a lack 
of randomization, leading to differences in age, sex and genetic background between 
the vaccinated and control groups; addressing these issues would have improved 
the study design, but carried the associated risk outlined previously.  
 
Amongst the limitations was that control foals were two months younger than 
vaccinated foals, which may have had an impact on their ability to mount an antigen 
specific immune response. The generation of an immune response is reliant on 
many factors including the ability of antigen presenting cells to stimulate T cells, T 
cell numbers, a favourable cytokine microenvironment to mediate co-stimulation of T 
and B cells and ultimately development of immune effector functions, including 
antibody synthesis of an appropriate isotype and CTL activity. In terms of foal age, 
most literature focusses on the immune ontogeny of the adaptive immune response 
to environmental antigens between birth and 6 months old. Holznagel et al [45] 
analysed immunoglobulin isotypes in 13 foals of mixed breeds at approximately 
monthly intervals from birth to 51 weeks of age, one of the few studies to monitor 
antibodies between 6 months of age, through puberty to adult hood. They reported 
stable concentrations of serum IgG1/2 (IgGa) or IgG5 (IgG(T)) and IgA at 8 weeks 
and 12 weeks respectively but IgG6 and IgG7 (IgGc) were not reported. Flaminio et 
al [46] showed that the absolute number of peripheral blood lymphocytes increased 
2.5 fold during the first 3 months of life but by 4 months of age, foals had their full 
repertoire of CD4 and CD8 lymphocytes. In addition, foals aged 1-5 months had a 
higher proportion of FoxP3+ cells in the circulating CD4+ CD25+ (T regulatory cell) 
population and possessed higher suppressor activity compared with their mothers 
[47]. Compared with adult horses, foals at 4 months of age demonstrated equivalent 
innate and adaptive immune functions, including lectin-mediated lymphocyte 
proliferation (indicative of a functional T cell receptor), lymphokine activated killer 
activity and oxidative burst activity [46, 48]. Similarly Major Histocompatibility 
Complex class II expression by T and B lymphocytes reached adult levels by 3-4 
months of age [46, 49]. Ryan et al. reported a lower frequency of IFN and IL-4 
secreting cells in 3-4 month old foals compared with adults [50]. Another study 
reported that IFN gene expression was similar in blood leukocytes from foals aged 
4, 5 and 6 months [51], suggesting that this parameter had matured. IFNproduction 
per cell was also equivalent in 6 and 10 month old foals (8 month old foals were not 
tested). However the number of IFN+ blood leukocytes appeared lower in foals aged 
6 months compared with 10 months [51].  These authors concluded that the mean 
level of IFN protein production in foals approached adult levels by 3 months of age. 
Ryan et al also reported a lower frequency of IFN and IL-4 secreting cells in 3-4 
month old foals compared with adults [50]. Demmers et. al. [52] demonstrated that 
total IgG concentrations were similar in 6 versus 8 month old foals. Antibody isotype 
analysis in foals aged 3-8 months, which encompasses the ages of the foals in the 
current study, showed that IgG1, IgG3 and IgG5 predominate quantitatively over 
IgG4/IgG7 [53]. The latter displays virus neutralizing activity [54].  Perkins & Wagner 
[55] re-analysed published data to show that IgG1 and IgG5 are equivalent 
quantitatively in foals at 6 and 8 months of age. However IgG7 (IgGc) shows a slow 
but gradual increase from a nadir at 3-4 months, to reach ~3g/l at 30 weeks then 4g/l 
by 50 weeks of age [45]. Thus the increased levels of VN antibody titre in the 
RacHgM vaccinated foals within the current study may in part be attributable to the 
greater capacity of older foals to synthesize this isotype compared with the younger 
controls. Nevertheless, this increase in IgG7 is part of immune ontogeny rather than 
measuring the ability of foals to respond to a viral antigen and mount primary and 
secondary immune responses. There is some evidence of variation in antigen-
specific immune responses with age, particularly very young foals. For example, 
foals vaccinated with keyhole limpet haemocyanin at 3 days old, followed by booster 
vaccination showed a diverse immunoglobulin repertoire and the ability to switch 
isotype as measured by sequencing of the B cell immunoglobulin variable region 
[56]. Three-month-old foals vaccinated twice intra-musculary at 3 week intervals with 
a killed cattle respiratory viral vaccine and adjuvant, mounted lower antigen specific 
proliferation and humoral immune responses compared with adults [57] suggesting 
that the adaptive immune response to this antigen is still immature at 3-4 months of 
age. In contrast, the influenza and tetanus IgG1/IgG2, IgG4 and IgG5 sub-isotype 
responses (IgGa, IgGb and IgG(T) respectively) of 6-month-old foals to vaccination 
with inactivated influenza virus, tetanus toxoid and adjuvant followed the same 
pattern as those shown by yearlings but titres were generally lower [58]. Further 
comparison of the results from control foals in the current study with data from 7 
month old, EHV-1 naïve, Icelandic foals infected with strain NY03 [59], showed 
similar patterns of pyrexia, nasopharyngeal virus shedding and cell-associated 
viraemia; the key difference was the longer duration of these signs in the current 
study. This difference may be a reflection of the strain used for infection or other 
unidentified host-related factors. On balance, the sparsity of published literature 
means that currently, it is impossible to draw any firm or precise conclusion about 
the impact of a two month age difference on the ability of weaned foals to generate 
immune responses to either EHV-1 RacH11gM and / or challenge infection. The 
majority of immune parameters studied appear mature at 4 months of age, with 
absolute IgG4 / IgG7 increasing gradually to adult hood [45]. Furthermore current 
guidelines states that primary vaccination of foals at 4-6 months of age is sufficient to 
generate an effective immune response to viral vaccines [35].  
 
Any effect of gender on immune responses in foals has not been reported to date. In 
people, gender plays a role in susceptibility to disease and response to vaccination, 
but any bias is dependent on the pathogen [60]. For example Fleming et al [61] 
reported a higher seroprevalence against herpesvirus-2 in adult females compared 
with males, while the incidence of varicella zoster infection was higher in women, but 
age-dependent [62]. Reproductive hormone status can also have an impact on the 
immune response, as many white blood cells express receptors for steroid and 
gonadal hormones [60]. For example, in adult people, oestrogens promote the Th2 
cytokine bias and thus activation of antibody production, but androgens tend to 
promote Th1 –dependent responses and activate CD8+ T lymphocytes, although 
progesterone can have immune-suppressive effects [63-65]. In the current study, the 
weaned foals were pre-pubertal; puberty in this species begins at approximately 10 
months and until then, is characterized by little testicular activity, but ovaries do have 
active steroidogenesis and thus low gonadotrophin and steroid concentrations [66-
68]. Thus the influence of reproductive hormones on the immune responses of the 
control and vaccinated foals, particularly females remains undetermined. 
 
As part of an unrelated project, the MHC class I haplotypes expressed by some foals 
were characterized. For intracellular pathogens such as EHV-1, MHC class I 
expression is crucial in antigen processing and ultimately in primed animals, the 
presentation and recognition of short viral peptides by cytotoxic T lymphocytes. 
Here, the two groups of foals were each sired by a single but different Welsh 
Mountain pony stallion and the genetics of the foals also differed, with one group 
expressing unknown MHC Class I haplotypes and the other showing a 
predominance of the MHC class I A3 and A7 haplotypes. Both these haplotypes are 
common in the Welsh Mountain pony breed (Prof D.F. Antczak, Cornell University, 
Personal Communication), thus it is likely that at least some of the control foals 
expressed these haplotypes and their associated alleles, making them potentially 
more genetically similar to the vaccinated group. In addition all vaccinates were 
heterozygous so both groups may have had similar genetic diversity, but this 
remains uncharacterized. Nevertheless a potential impact of genetic background 
must be considered when evaluating the outcome of this vaccine trial. 
 
There is evidence that infection of horses with different wild type strains of EHV-1 will 
stimulate cytokine responses with subtle differences [69]. Thus, the parent strain of 
an MLV may affect the nature and route of antigen presentation and thus the 
immune response generated. Here, vaccination with the prototype MLV based on 
RacH11 primed humoral immune responses effectively. Vaccination of a third group 
of foals with the parent RacH strain would have enable more detailed 
characterization of the precise role of gM in immune-enhancement and protection 
against EHV-1 challenge infection as reported in mice [29].  However experimental 
infection of yearling or 2-4 year old ponies with either strain Ab4ORF1/2 or 
Ab4ORF2 resulted in pyrexia and nasopharyngeal shedding of a lower magnitude 
and shorter duration compared with wild type Ab4, but no difference in cell 
associated viraemia [70, 71]. These data are in contrast to the current study where 
RacHgM vaccination (in which ORF 1/ 2 are deleted) did result in reduced cell-
associated viraemia on challenge in infection, along with reduced clinical signs and 
nasopharyngeal shedding. 
 
It had been anticipated that the MLV vaccine would prime antigen specific cell 
mediated immunity via its replication then presentation of viral antigens to CTL by 
MHC class I molecules. Strain RacL11, from which RacH was derived, also causes 
moderate MHC class I downregulation in infected host cells in vitro compared with 
strain Ab4; this is largely due to the absence of ORF1 (EHV-1 UL1; pUL56 HSV 
homologue) [72]. ORF2 (EHV-1 UL2; no HSV homologue identified) which 
modulates cytokine responses is also absent [17].  The ORF17 (gene pUL43) 
collaborates with ORF1 (pUL56) in the downregulation of MHC class I in strain Ab4 
[73]. However, ORF17 is present in strain RacL [17] and to the author’s knowledge, 
there are no reports to suggest it has been deleted during the attenuation of RacH. 
Thus the impact of RacHgM on MHC class I expression is likely to reflect the 
parental RacL strain. Nevertheless, in vivo the replication of EHV-1 occurs 
sequentially at primary and secondary sites, so it is unlikely that downregulation of 
MHC class I occurs in all infected cells simultaneously. Thus antigen presentation by 
MHC class I molecules to CTL is predicted to continue. Despite this prediction and 
although there was a suggestion that RacH11gM vaccination primed CTL activity, 
this was insignificant and individual responses were variable. One potential 
explanation and in common with other viruses and species [74, 75], is that the host’s 
genetic background, particularly MHC class I haplotypes may impact the magnitude 
of the CTL response. Unlike in-bred mice, the recruitment of genetically identical 
horses is challenging and despite being the same breed, the foals in the current 
study were not in-bred. This potential confounding factor needs consideration when 
interpreting the data. 
 
Despite deletion of EHV-1 gM, RacHgM retains the ability to penetrate, spread from 
cell-to-cell and egress from host cells [29]. This glycoprotein is also a moderate 
tetherin antagonist, potentially permitting release of virions trapped on host cells and 
allowing further dissemination [76]. It may be that the RacHgM vaccination resulted 
in a more limited release of virions from host cells, but antigen processing and 
presentation continued, permitting the development of robust systemic humoral 
immunity but a more limited priming of CTLs. Vaccination with the RacH vector alone 
would have permitted further insights into the role of gM in the generation of selected 
immune responses. 
 
Intranasal administration of the RacHgM mutant in combination with an 
intramuscular prime was predicted to result in the stimulation of mucosal antibody, 
particularly IgA and thus contribute to protection against EHV-1 challenge infection in 
vaccinated foals. Simultaneous intranasal and intramuscular administration of an 
MLV provided good protection against challenge infection with bovine herpesvirus-1 
[77]. Here, no significant difference in corrected OD values for nasopharyngeal IgA 
and IgG was detected in the control versus vaccinated foals. Instead there was a 
general increase in mean corrected OD values for IgA and IgG throughout the 
sample period. A similar failure of an intranasally administered, live attenuated 
vaccine (Rhinomune®; RacH strain) administered exclusively within the nares to 
stimulate EHV-1 specific mucosal IgA or IgG or serum antibody in weaned foals was 
reported previously [23]. This was in contrast to the intranasal administration of strain 
A183, which stimulated virus specific mucosal IgA effectively, for a duration of at 
least 13 weeks [23].  However Dolby et al [78] reported that intramuscular 
administration of EHV-1 strain V592 with Freunds’ complete and incomplete 
adjuvants successfully primed the mucosal immune response, resulting in detectable 
mucosal IgA on challenge infection. Thus, as well as the route of administration and 
antigen, adjuvants are likely to play an important role in the generation of mucosal 
immunity [79, 80]. Another contributing factor to the relative absence of 
nasopharyngeal antibody may be the nasopharyngeal muco-ciliary clearance 
system, particularly the mucus component, which may have trapped and removed 
the majority of RacHgM virions at this location. The main component of mucus is 
secreted mucins and these are composed of heavily glycosylated glycoproteins 
which form a complex mesh, with pore size dictating the size and charge of particles 
which can enter the mucus [81]. In horses, MUC5B and MUC5AC form the major 
and minor components in equine respiratory secretions respectively [82]. In vitro, the 
movement of pseudorabies virus, was 59 fold slower in porcine mucus compared 
with water and this hindrance was related to charge, rather than size alone (Yang et 
al 2012). EHV-1 has a zeta potential of -33mV (J.H. Kydd, unpublished data) and is 
approximately 266nm in diameter which is similar to pseudorabies virus (zeta charge 
-31.8+1.5mV; [83]. Thus the respiratory mucus may have limited access of the 
RacH11gM vaccine to the underlying epithelial cells and local immune system. This 
in turn may have resulted in EHV-1 failing to reach the lamina propria and stimulate 
IgA production by cognate plasma cells and transudation or FcRn mediated transport 
of selected IgG isotypes to the apical aspect of the mucosal epithelium and thus 
prohibit any post-vaccination increase in mucosal antibody [84-86]. The absence of 
mucosal IgA and IgG following vaccination of ponies with a gM deletion mutant may 
also be explained by the virus failing to, or at least showing limited binding and entry 
to the respiratory epithelium. An equine respiratory epithelial cell model (EREC) has 
shown that EHV-1 uses cellular N-linked glycans as receptors for initial EHV-1 
binding and entry and thus infection of epithelial cells. These receptors are located 
on the basolateral aspect of ERECs and are normally inaccessible to EHV-1 when 
the  epithelium is intact [87]. This phenomenon would also prevent antigen reaching 
plasma cells within the lamina propria and explain the absence of mucosal antibody. 
Yet another contributing factor to the relative absence of nasopharyngeal antibody 
may be a failure of RacH11gM to replicate sufficiently, perhaps due to degradation 
by mucosal enzymes, such as lysozyme [88]. Thus it may be that a combination of 
mucus and intact respiratory epithelium limited replication in the respiratory tract 
following intranasal vaccination with a RacHgM deletion mutant, thus failing to 
prime mucosal immunity with no consequent exponential increase in virus specific 
IgA and IgG responses. The form (MLV and / or inactivated) and route (intranasal 
and / or intramuscular) of concurrent inoculation can influence protection against 
challenge infection, as highlighted for BHV-1 [77].  Moreover, in horses, separate 
intramuscular prime, followed by an intranasal boost by vaccination or infection did 
stimulate equine influenza or EHV-1 specific mucosal antibody responses [38, 78]. 
However, although intranasal vaccination of foals with the RacH11gM failed to 
stimulate mucosal antibody, it may have generated effector CTL activity in 
respiratory lymphoid tissue, as has been reported for strain A183 [89], contributing to 
partial protection.  
 
The protective efficacy of other MLV or gene deletion mutant vaccines against 
respiratory viruses has been reported in horses. For example, intramuscular 
vaccination of adult horses with MLV Prevaccinol® or Rhinomune® reduced 
nasopharyngeal shedding and viral DNA or infectious virus in blood [21, 22, 90, 91]. 
van de Walle and colleagues generated an MLV (NY03IR6/1) that mimicked 
mutations in EHV-1 strain RacH [42]. Intramuscular and subcutaneous vaccination of 
susceptible horses aged 2 to 18 years generated high titres of virus neutralizing 
antibody. On challenge infection, the amount and duration of nasopharyngeal 
shedding was significantly shorter compared with controls and no pyrexia or cell 
associated viraemia was detected.  Experimentally, some EHV-1 gene deletion 
mutants (e.g. gene 38 (thymidine kinase) and gE / gI deletions) have shown 
virulence after vaccination [92-94], while others gave no or partial protection on 
challenge infection [12, 95]. In Japanese Thoroughbred racehorses, a live attenuated 
EHV-1 / EHV-4 vaccine (ERPL, Nisseiken, Tokyo, Japan) which is licensed for 
prevention of respiratory disease and abortion has been introduced successfully at 
one training centre [14]. This vaccine stimulated higher VN antibody titres than the 
inactivated virus vaccine used previously and was also associated with a reduction in 
the frequency of EHV-1 outbreaks [14].  Of note, several studies which used Ficoll 
gradient centrifugation to isolate PBMC report a high viral load as assessed by 
quantitative PCR, but no infectious virus was detected during co-cultivation on 
indicator cells [21, 23], which appears illogical. Overall, commercial EHV-1 vaccines 
containing either MLV or inactivated virus can stimulate components of humoral and 
cell mediated immune responses effectively, when administered individually [22] and 
some are associated with partial virological protection against respiratory disease . 
Consequently, to exploit these known benefits and improve protection, it may be 
timely to re-evaluate conventional vaccination strategies and consider for example, 
the combined use of MLV and inactivated virus vaccines, as well as optimization of 
adjuvants and routes, timing and frequency of administration [59, 88].  
 
In conclusion, intramuscular and intranasal vaccination of weaned foals with an 
EHV-1 RacH11gM mutant primed systemic humoral immune responses, but no 
significant mucosal antibody or CTL activity could be detected. By comparison with 
control foals, these responses were associated with improved but incomplete 
protection of vaccinated foals against challenge infection. Complete prevention of 
nasopharyngeal virus shedding and cell associated viraemia by vaccination remains 
a challenging goal for future EHV-1 research.  
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Table 1. Details of weaned foals used in the EHV-1 RacH11gM vaccine trial. Major 
histocompatibility Complex (MHC) class I haplotype had been determined previously 
by microcytotoxic lymphocyte assay. V1 = first vaccination. CI = challenge infection. 
n/a = not applicable. M = month. * two stallions were used and each sired the foals in 
one group only. 
 
Foal no. Gender  Date of birth Age at V1 Age at CI Dam MHC Sire MHC*




144D Female 24th June n/a 210 unknown unknown 
6633 Female 16th July n/a 188 unknown unknown 
4033 Female 17th July n/a 187 unknown unknown 
4933 Female 17th July n/a 187 unknown unknown 
4150 Female 24th July n/a 180 unknown unknown 
4B05 Female 30th July n/a 174 unknown unknown 
Mean + standard deviation   187.7+12.2  
     6.2+0.4 m 
 
Vaccinates 
4568 Male 11th April 184 254 A3/x A7/x 
6825 Male 30th April 195 265 A3/x A7/x 
1B05 Male 10th May 185 255 A3/x A7/x 
6A77 Female 14th May 181 251 A7/x A7/x 
1105 Female 16th May 179 249 A3/x A7/x 
7728 Male 21st May 174 244 A3/x A7/x 
Mean + standard deviation  183+7.1 253+7.1 
    6.1+0.2 m 8.4+0.2m 
  
Figure legends. 
Figure 1. Timeline of EHV-1 RacHgM vaccine trial in weaned foals. V1 and V2 = 
first and second vaccinations respectively. 
 
Figure 2. EHV-1 specific antibody titres in serum samples collected from control and 
vaccinated foals at different stages of the EHV-1 RacHgM vaccine trial. 
Seroconversion of either complement fixing (CF) or virus neutralizing (VN) antibody 
was defined as an increase of log10 0.6 in titre. * indicates a significant difference 
(p<0.001) between the antibody titres in the control group compared with the 
vaccinated group. m= months, w = weeks.  
a) complement fixing antibody. A reciprocal CF titre of log10 1.9 (> 1:80) is indicative 
of exposure.  Comparison of V1-3m with other time points in vaccinated foals: “a” not 
significant, “b”, “c”, “d” indicate p<0.05, with significance levels of a<b<c<d, with d 
the highest level of significance at p<0.001.  
b) virus neutralizing antibody. Comparison of V1+0 (pre-vaccination) with other time 
points in vaccinated foals: “a” not significant; “b” p<0.001. 
 
Figure 3. Clinical and virological parameters in control and RacHgM vaccinated 
foals following intranasal challenge infection with EHV-1 strain Ab4/8. a) rectal 
temperature; b) nasopharyngeal virus shedding; c) percent of foals with detectable 
cell associated viraemia. Samples for viraemia testing used buffy coat cells, which 
were not purified on sucrose density gradients. No samples were collected on Day 8 
after infection. 
 
Figure 4. EHV-1 specific IgA and IgG immunoglobulins in nasal washes from control 
and vaccinated foals at different stages of the EHV-1 RacHgM vaccine trial. Data 
are expressed as corrected optical densities (OD) namely relevant immunoglobulin 
(Ig) OD – non specific binding / protein concentration in neat nasal wash (mg/ml). 
Mean corrected positive and negative control OD values for each group assayed 
were: IgA unvaccinated foals 0.51+0.20 and 0.20+0.04; IgA vaccinated foals 
0.57+0.14 and 0.09+0.03; IgG unvaccinated foals 0.37+ 0.17 and 0.07+0.03; IgG 
vaccinated foals 0.30+0.19 and 0.06+0.01 respectively. a) IgA control foals; b) IgA 
vaccinated foals; c) IgG control foals; d) IgG vaccinated foals.  
 
Figure 5. EHV-1 specific cytotoxic T lymphocyte (CTL) responses in peripheral blood 
lymphocytes collected from control and vaccinated foals at different stages of the 
EHV-1 RacHgM vaccine trial. Final mean percent specific lysis by effector cells 
after subtraction of percent lysis against mock infected target cells is shown. Each 
sample was assayed in triplicate. Effector to target ratios are shown. a) control foals; 
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Supplementary Table 1. Log10 VN antibody titres/ml before and after vaccination and following EHV-1 challenge infection  
 
 
Foal Number Sample Point 
 




 4B05 2.15 1.55 1.95 >3.15 
 4033 1.44 1.14 >3.15 >3.15 
 4933 1.35 0.75 2.45 3.05 
 6633 1.35 0.55 2.64 >3.15 
 144D 1.14 1.14 >3.15 >3.15 
 4150 1.14 0.75 2.94 >3.15 
 
 Mean 1.48+0.37 0.98+0.37 2.71+0.47 3.13+0.04 
 
Vaccinates: 
 7728 0.75 2.55 3.05 >3.15 
 1B05 2.25 >3.15 >3.15 >3.15 
 6825 2.15 >3.15 >3.15 >3.15 
 4568 2.15 2.94 >3.15 >3.15 
 1105 1.85 1.95 3.05 3.05  
 6A77 1.14 2.85 >3.15 >3.15 
 
 Mean 1.71+0.62 2.76+0.46 3.12+0.05 3.13+0.04 
Supplementary Table 2.  Mean clinical scores, pyrexia, nasopharyngeal (NP) shedding and cell associated viraemia in control or gM- 
vaccinated foals following intranasal challenge infection with EHV-1, strain Ab4/8. The presence of mucopurulent nasal or ocular discharge at 
each nostril or eye and submandibular lymph node enlargement were assessed and scored as 0 (absent), 1 (present, mild), 2 (present, 
moderate) or 3 (present, severe). Total = total number of days, then first and last day of detection. 
  
 
 Foal status Clinical Score Pyrexia NP virus shedding Cell associated viraemia 
 
    (Days)   (Days)    (Days) 




 Mean 21.2 4.5 2.0 5.5 8.3 1.3 8.8 6.2 3.0 15.3 
  




 Mean 8.3 1.2 3.0 3.7 2.8 1.2 4.0 2.5 4.7 8.3    
 St Dev 6.2 1.0 2.4 2.7 2.3 0.7 3.6 0.5 0.8 2.1 
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